Immune Landscape of Pancreatic Cancer Development and Drug Resistance

Batoul Farran is an associate scientist in the Department of Oncology at the Albert Einstein College of Medicine, USA. She obtained her PhD in Structural and Molecular Biology from University College London, UK. She completed her postdoctoral fellowship at the Department of Hematology and Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, USA. Her work focuses on translational cancer research, specifically on targeted and immune therapies in colorectal, pancreatic and lung cancers. She has authored several publications in highly reputed international journals. Dr. Nagaraju obtained his MSc and his PhD, both in Biotechnology, from Sri Venkateswara University in Tirupati, Andhra Pradesh, India. He received his DSc from Berhampur University in Berhampur, Odisha, India. Dr. Nagaraju’s research focuses on translational projects related to gastrointestinal malignancies. He has published over 100 research papers in highly reputed international journals and has presented more than 50 abstracts at various national and international conferences. Dr. Nagaraju is author and editor of several published books for Elsevier and Springer Nature. He serves as editorial board member of several internationally recognized academic journals. Dr. Nagaraju has received several international awards including FAACC. He also holds memberships with the Association of Scientists of Indian Origin in America (ASIOA), the Society for Integrative and Comparative Biology (SICB), The Science Advisory Board, The RNA Society, The American Association for Clinical Chemistry (AACC) and the American Association of Cancer Research (AACR).

• 1. Introduction2. Molecular profiling and mutational landscape of pancreatic cancer3. Tumor microenvironment and immune components interaction in pancreatic ductal adenocarcinoma4. Identification of immune targeted molecules in pancreatic ductal adenocarcinoma5. Targeting macrophages for pancreatic cancer therapy6. Targeting cancer-associated fibroblasts in pancreatic ductal adenocarcinoma7. Targeting short-lived immunosuppressive myeloid cells for PDAC therapy8. Targeting T-regs in PDAC9. Immune-modulators for PDAC therapy10. Current clinical trials in PDAC immunotherapy11. Precision medicine in PDAC immunotherapy12. Artificial intelligence in pancreatic cancer immunotherapy